Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine for curing chronic primary glomerular disease and preparation method thereof

A glomerular disease, primary technology, applied in the field of medicine, can solve problems such as toxic and side effects, achieve the effects of improving clinical symptoms, facilitating process research and quality control, and improving protein metabolism

Inactive Publication Date: 2019-03-01
湖北省中医院
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] In summary, the existing problems in the prior art are: the treatment of chronic primary glomerular diseases in modern medicine mainly adopts diet control, lowering urine protein, controlling blood pressure, etc., and the drugs are mainly concentrated in hormones, immunosuppressants, Angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARBs), etc., but long-term use of hormones and immunosuppressants have relatively serious side effects, and RAS blockers are also effective in delaying the progression of CKD. limited

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine for curing chronic primary glomerular disease and preparation method thereof
  • Medicine for curing chronic primary glomerular disease and preparation method thereof
  • Medicine for curing chronic primary glomerular disease and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0029] Such as figure 1 As shown, the preparation method of the medicine for the treatment of chronic primary glomerular disease provided by the embodiments of the present invention comprises the following steps:

[0030] S101: Drug preparation: Astragalus 500g, Fangji 167g, bran-fried Atractylodes macrocephala 200g, Viola 250g, silkworm 167g, psyllium 167g, Poria cocos 167g, raspberry 200g, roasted licorice 100g;

[0031] S102: Add 8 times the amount of water to the above nine flavors, decoct three times for 1.5 hours each time, combine the decoctions, filter, condense into a thick extract, dry to obtain dry extract powder, and use a ratio of 1:1.1 (extract powder : dextrin) and add dextrin in the left and right proportions to make 1000g, mix well;

[0032] S103: Granulate with 75% ethanol, dry at 60-75°C, granulate, make into granules, pack separately, specification 10g / bag.

[0033] After research and development, the drug is roughly extracted and processed into granule d...

Embodiment 1

[0045] In the following, combined with the available plan, the blind method is used to carry out clinical observation on patients with CKD stage 1-3 (Qi deficiency and rheumatism internal disturbance syndrome);

[0046] Adopt the western medicine benazepril that the present invention is compared with conventional treatment primary chronic glomerulonephritis;

[0047] (1) Specific plans include:

[0048] 1. Blinding method

[0049]All qualified patients will be randomly divided into three groups for observation according to the ratio of 1:1:1. The random numbers are provided by statistical professionals and generated by SAS software simulation. The statisticians will complete the blind editing of drugs and the preparation of random envelopes and emergency letters. Fangji Huangqi Granules and Fangji Huangqi Granule Simulators will be randomly coded as No. 1 and No. 2 drugs by the statisticians, and Benazepril and Benazepril analogs will be randomly coded as No. 3 and No. 4 dru...

Embodiment 2

[0209] (1) Clinical data:

[0210] 1. Case source

[0211] A total of 180 outpatients or inpatients in the Nephrology Department of Hubei Provincial Hospital of Traditional Chinese Medicine were collected from June 2009 to June 2014. Those who meet the diagnostic criteria of CKD, blood pressure controlled within 140 / 90mmHg; eGFR ≥ 30ml / min, that is, patients with CKD stage 1-3; TCM syndromes that meet the syndrome of kidney qi deficiency and internal disturbance of rheumatism. All patients signed an informed consent form approved by the Ethics Committee.

[0212] 2. Diagnostic criteria of TCM syndromes:

[0213] Syndrome of qi deficiency and internal disturbance of rheumatism:

[0214] Main symptoms: backache and fatigue, foamy urine, or gross hematuria.

[0215] Secondary symptoms: ①shortness of breath, lazy speech, edema, ③evil wind, easy to catch a cold, ④spontaneous sweating, ⑤soreness of head, body, muscles, limbs, ⑥skin eczema, itching

[0216] Diagnosis can be made...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of medicine, and discloses a medicine for curing a chronic primary glomerular disease and a preparation method thereof. The medicine for curing the chronicprimary glomerular disease is prepared from the materials by weight: 30g of radix astragali seu hedysari, 10g of radix stephaniae tetrandrae, 12g of stir-fried with branrhizoma atractylodis macrocephalae, 15g of herba violae, 10g of bombyx batryticatus, 10g of plantaginis seed, 10g of poria cocos, 12g of fructus rubi and 6g of honey-fried radix glycyrrhizae. The medicine is subjected to rough extraction and is processed into a granule formulation shape. According to the medicine for curing the chronic primary glomerular disease and the preparation method thereof, the formulation is pure traditional Chinese medicine, and the medicine is safe and has no side-effect; the medicine has the efficacy of strengthening a spleen,tonifying a kidney, invigorating qi, consolidating superficies, dispelling pathogenicwind and eliminating dampness, mainly cures the chronic primary glomerular disease, and particularly cures a patient with symptoms of qi deficiency and edema; a chronic kidney disease patient is suitable to take the medicine for a long-term; the clinical oral doses are few, the curative effect is significant, the medicine can effectively facilitate regression of the edema, improve the clinical symptoms, and postpone the disease progression of the chronic primary glomerular disease; and a ranged of applying public is wide, and the medicine can produce social effects well and bring economic effects for the society.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a medicine for treating chronic primary glomerular diseases and a preparation method thereof. Background technique [0002] At present, the existing technologies commonly used in the industry are as follows: [0003] Chronic kidney disease (CKD, chronic kidney disease) is a major disease that seriously endangers human health, and is currently growing at an alarming rate worldwide. The final outcome of CKD is end-stage renal disease (ESRD), which must rely on renal replacement therapy, which not only has a high mortality and disability rate, but also consumes huge medical and health resources. The prevention and treatment of CKD has become a global public health event. [0004] There are many etiologies of CKD, including primary and secondary kidney damage. my country's 1999 national dialysis data registration suggests that chronic primary glomerular disease is the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/86A61P13/12A61K35/64
CPCA61K35/64A61K36/076A61K36/284A61K36/481A61K36/484A61K36/59A61K36/68A61K36/73A61K36/86A61K2236/331A61K2236/39A61P13/12A61K2300/00
Inventor 王小琴邹新蓉王岚周全袁军周慧兰吴艳萍程虹薛雪吴文静丁秀韩四评
Owner 湖北省中医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com